

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2023/019223 A3

(43) International Publication Date
16 February 2023 (16.02.2023)

(51) International Patent Classification:

A61K 38/17 (2006.01) *C07K 16/46* (2006.01)
A61P 37/06 (2006.01) *C07K 19/00* (2006.01)
C07K 14/715 (2006.01)

Published:

— with international search report (Art. 21(3))

(88) Date of publication of the international search report:

28 September 2023 (28.09.2023)

(21) International Application Number:

PCT/US2022/074868

(22) International Filing Date:

11 August 2022 (11.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/232,124 11 August 2021 (11.08.2021) US

(71) Applicant: **AKSO BIOPHARMACEUTICAL INC.**

[US/US]; 1801 Century Park East, Ste 1901, Los Angeles,
California 90067 (US).

(72) Inventors: **GIACCIA, Amato J.**; Cherry Orchard, Ver-

non Avenue, Oxford OX2 9AU (GB). **MIAO, Yu**; 808 Ju-
lian Ter, #5, Sunnyvale, California 94085 (US). **ZHANG,**
Xin Eric; 23 High Water, Newport Coast, California 92657
(US).

(74) Agent: **LOGAN, Janice H.**; c/o Morgan, Lewis & Bockius

LLP, 1111 Pennsylvania Ave NW, Washington, District of
Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS OF REDUCING PRODUCTION OF IgA, IgM AND/OR IgG USING sBCMA VARIANTS AND FC FUSION PROTEINS THEREOF

(57) Abstract: This invention is directed to methods of reducing immunoglobulin production (e.g. IgA, IgM, and/or IgG, etc.) in subjects diagnosed with an autoimmune disease and/or fibrosis comprising administering to the subjects compositions comprising sBCMA variants and/or sBCMA variant – Fc fusion proteins.

WO 2023/019223 A3